跳到正文
原文
GEN Genetic Engineering & Biotech· Julianna LeMieux, PhD·· 1 天前AI 评分42

Science Translational Medicine发表研究:靶向FOLR1逆转小鼠结直肠癌对免疫治疗的耐药

Targeting Folate Receptor Reverses Colorectal Cancer’s Resistance to Immunotherapy in Mice

AI 导读

《Science Translational Medicine》发表的研究在小鼠中显示,抗FOLR1抗体偶联药物mirvetuximab soravtansine恢复了抗肿瘤免疫力,并使结直肠癌重新对anti-PD-1阻断治疗敏感。研究发现高表达FOLR1可预测较差的ICB反应和不利患者结局;机制上FOLR1通过稳定AARS1导致STAT1去磷酸化,间接抑制CD8+ T细胞活性。

正文

Colorectal cancer (CRC) is the third most common cancer worldwide. Although immune checkpoint blockade is promising, responses to the treatment have been limited: treatments such as anti-PD-1 have resulted in only 15% of patients experiencing substantial benefits.

Now, a new study shows that a receptor for folate sustains colorectal cancer’s ability to evade a form of cancer immunotherapy—and finds that targeting this receptor with an approved compound can restore the treatment’s cancer-killing power in mice. The data add to the understanding of what factors can shape colorectal cancer’s response to immunotherapy and suggest that integrating folate receptor-based treatments into existing regimens could improve outcomes in patients with treatment-resistant tumors.

This work is published in Science Translational Medicine in the paper, “Targeting cancer immune evasion with anti-FOLR1 antibody-drug conjugate potentiates anti-PD-1 efficacy in colorectal cancer.”

Colorectal cancer tumors possess many properties that stall immunotherapy’s ability to enhance anti-tumor immunity, including defects in the expression of MHC-1. Indeed, loss of MHC-I antigen presentation in tumor cells drives immune evasion and resistance to immune checkpoint blockade in colorectal cancer.

Previous research has connected folate receptor α (FOLR1) to more aggressive disease progression and poorer prognoses in various types of solid tumors. In this study, researchers conducted fluorescence-activated cell sorting–based CRISPR activation screens using a druggable genome library and identified folate receptor α (FOLR1) as a top negative regulator. In the study, they found that “high expression of FOLR1 predicted a poor ICB response, enhanced cancer stemness, and unfavorable patient outcomes.”

In addition, the team’s proteomic analyses revealed that “FOLR1 stabilized the lactyltransferase AARS1 (alanyl-tRNA synthetase 1), which lactylated signal transducer and activator of transcription 1 (STAT1) at lysine-193 (K193), facilitating its interaction with TCPTP (T cell protein-tyrosine phosphatase) and inducing STAT1 dephosphorylation at tyrosine-701.”

The group also tested the potential of mirvetuximab soravtansine, an approved antibody-drug conjugate that inhibits FOLR1. In vitro experiments revealed that FOLR1 indirectly impaired the activity of the STAT1 signaling pathway and dampened MHC-1 activity, which supported the cancer cells’ adaptability and prevented CD8+ T cells from engaging tumor cells.

However, mirvetuximab soravtansine restored anti-tumor immunity and resensitized colorectal cancer tumors to anti-PD-1 blockade in mice.

“Our findings support anti-FOLR1 [antibody-drug conjugate] as a clinically actionable approach to overcome immune evasion and unlock immunotherapy efficacy in [colorectal cancer],” the authors write.

The post Targeting Folate Receptor Reverses Colorectal Cancer’s Resistance to Immunotherapy in Mice appeared first on GEN - Genetic Engineering and Biotechnology News.

来源:GEN Genetic Engineering & Biotech · genengnews.com